What is the clinical evidence from this study?

Study design: Review. Population: Heterozygous familial hypercholesterolemia (heFH). Intervention: Statin and ezetimibe combination therapy.

November 1, 2010Vascular Health and Risk ManagementOpen Access

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

View Full Paper

Ask AI

Bookmark

Key result

Combination therapy of statin and ezetimibe effectively achieves near-normal lipid profiles in patients with heterozygous familial hypercholesterolemia.

Why the study?

Does combination therapy of statin and ezetimibe improve lipid profiles and reduce cardiovascular risk in patients with familial hypercholesterolemia?

Population

Adult, pediatric, and adolescent patients with heterozygous familial hypercholesterolemia or primary…

Design

Review

Authors

HHamilton-CraigGriffith University

Discussion

Member takes

Implication

Short-term ezetimibe-statin combination appears effective and safe in children with heFH; leaves open long-term outcomes and optimal regimens.

Structured PICO

Does combination therapy of statin and ezetimibe improve lipid profiles and reduce cardiovascular risk in patients with familial hypercholesterolemia?

Population

Adult, pediatric, and adolescent patients with heterozygous familial hypercholesterolemia (heFH) or primary hypercholesterolemia

Intervention

Combination therapy of high-dose potent statin and ezetimibe

Outcome

Reduction in levels of low-density lipoprotein cholesterol (LDL-C) and improvement in risk for cardiovascular diseasesurrogate

Statin and ezetimibe combination therapy is an effective and safe standard of care for achieving near-normal lipid profiles in patients with heterozygous familial hypercholesterolemia.

Limitations

Data are limited in children and adolescents, for whom longer-term studies are required.
Few data support a pleiotropic action of ezetimibe with regard to CVD benefit.
Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation.
Limited long-term safety and efficacy data in children and adolescents
Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation
Unlikely that a large long-term randomized controlled clinical outcomes trial will ever be performed in patients with FH

Cite This Study

Hamilton-Craig (2010) conducted a review in Heterozygous familial hypercholesterolemia (heFH). Statin and ezetimibe combination therapy was evaluated. Combination therapy of statin and ezetimibe effectively achieves near-normal lipid profiles in patients with heterozygous familial hypercholesterolemia.

synapsesocial.com/papers/6a6b9f1201245da06ecb89ce https://doi.org/10.2147/vhrm.s13496

Topics

Statin therapy Lipid management

View Full Paper

Ask AI

Bookmark

Implication

Short-term ezetimibe-statin combination appears effective and safe in children with heFH; leaves open long-term outcomes and optimal regimens.

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider